Biotech company Rigvir Group, who owns a registered oncolytic virotherapy medicine (RIGVIR®) is looking for partners globally to finance the commercialization process of a next generation solution for unmet medical needs in oncology based on the existing product.
We have elaborated a registration roadmap for unmet medical needs – early Melanoma and Uveal Melanoma treatment – considering the following:
It is expected that the company value would rise 3 times within the next two years but in 5 to 7 years period – 10 times, at least.
Clinical studies from 1968
First genetically non-modified virus
One of the fastest growing biotech companies of the Northern Europe
Proven in clinical practice for more than 10 years